Increment in NAD+ levels compared to placebo group which observed an increase of only 14.3% at day 60.


Enhancement of walking endurance compared to 3.4% observed in placebo group at the end of the study.

Improvement in quality of life in NMN group compared to the placebo group.

Reduction in Mean Fasting Sugar (HOMA-IR Index) in the Uthever group compared to the placebo group.

Improvement in sleep latency, sleep quality score, and fatigue, particularly in the NMN_PM group.